Aminoacyl tRNA Synthetase-Interacting Multifunctional Protein 1 Acts as a Novel B Cell-Activating Factor In Vitro and In Vivo
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Myun Soo | - |
dc.contributor.author | Kim, Tae Sung | - |
dc.date.accessioned | 2021-09-04T16:04:26Z | - |
dc.date.available | 2021-09-04T16:04:26Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-05-15 | - |
dc.identifier.issn | 0022-1767 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/93546 | - |
dc.description.abstract | Endogenous B cell-activating factors play pivotal roles in defense mechanisms by regulating B cell responses. We previously reported that aminoacyl tRNA synthetase-interacting multifunctional protein 1 (AIMP1) functions as a novel proinflammatory cytokine that activates macrophages and dendritic cells. However, roles of AIMP1 in B cell responses have not been studied. In this study, we investigated the effects of AIMP1 on B cell responses and their underlying mechanisms. AIMP1 induced the expression of surface activation markers on murine B cells and the proliferation of B cells. Additionally, AIMP1 increased the expression of activation-induced deaminase and class switch recombination in B cells. AIMP1 also had synergistic effects on B cell activation when combined with CD40 stimulus. Intracellular signaling experiments showed that AIMP1 activated B cells through a protein kinase C/NF-kappa B signaling pathway. Importantly, i.v. injection of AIMP1 into mice increased the expression of CD69 on splenic B cells and significantly enhanced Ag-specific Ab production. Taken together, our results show that AIMP1 acts as a novel B cell-activating factor. AIMP1-mediated B cell activation and the involvement of AIMP1 in diseases will provide additional information for therapeutic strategies. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AMER ASSOC IMMUNOLOGISTS | - |
dc.subject | CLASS SWITCH RECOMBINATION | - |
dc.subject | GERMINAL-CENTERS | - |
dc.subject | AIMP1/P43 | - |
dc.subject | CD23 | - |
dc.subject | IGA | - |
dc.subject | PROLIFERATION | - |
dc.subject | HOMEOSTASIS | - |
dc.subject | MATURATION | - |
dc.subject | DISEASE | - |
dc.subject | MICE | - |
dc.title | Aminoacyl tRNA Synthetase-Interacting Multifunctional Protein 1 Acts as a Novel B Cell-Activating Factor In Vitro and In Vivo | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Tae Sung | - |
dc.identifier.doi | 10.4049/jimmunol.1401352 | - |
dc.identifier.scopusid | 2-s2.0-84929094975 | - |
dc.identifier.wosid | 000353728800015 | - |
dc.identifier.bibliographicCitation | JOURNAL OF IMMUNOLOGY, v.194, no.10, pp.4729 - 4736 | - |
dc.relation.isPartOf | JOURNAL OF IMMUNOLOGY | - |
dc.citation.title | JOURNAL OF IMMUNOLOGY | - |
dc.citation.volume | 194 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 4729 | - |
dc.citation.endPage | 4736 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordPlus | CLASS SWITCH RECOMBINATION | - |
dc.subject.keywordPlus | GERMINAL-CENTERS | - |
dc.subject.keywordPlus | AIMP1/P43 | - |
dc.subject.keywordPlus | CD23 | - |
dc.subject.keywordPlus | IGA | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordPlus | HOMEOSTASIS | - |
dc.subject.keywordPlus | MATURATION | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | MICE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.